147 related articles for article (PubMed ID: 34146191)
21. Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies.
Liu S; Shah DK
AAPS J; 2023 Apr; 25(3):48. PubMed ID: 37118220
[TBL] [Abstract][Full Text] [Related]
22. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.
Patidar K; Pillai N; Dhakal S; Avery LB; Mavroudis PD
J Pharmacokinet Pharmacodyn; 2024 Feb; ():. PubMed ID: 38400996
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration.
Bussing D; Li Z; Li Y; Chang HP; Chang HY; Guo L; Verma A; Shah DK
AAPS J; 2021 Nov; 23(6):116. PubMed ID: 34750690
[TBL] [Abstract][Full Text] [Related]
24. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
Heiskanen T; Heiskanen T; Kairemo K
Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663
[TBL] [Abstract][Full Text] [Related]
25. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
Abuqayyas L; Balthasar JP
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
[TBL] [Abstract][Full Text] [Related]
26. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
Niederalt C; Kuepfer L; Solodenko J; Eissing T; Siegmund HU; Block M; Willmann S; Lippert J
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):235-257. PubMed ID: 29234936
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
28. Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice.
Khot A; Matsueda S; Thomas VA; Koya RC; Shah DK
J Pharmacol Exp Ther; 2019 Mar; 368(3):503-513. PubMed ID: 30622170
[TBL] [Abstract][Full Text] [Related]
29. Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE).
Chang HP; Cheung YK; Shah DK
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807057
[TBL] [Abstract][Full Text] [Related]
30. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
Glassman PM; Balthasar JP
Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
[TBL] [Abstract][Full Text] [Related]
31. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
32. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
33. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
Chang HY; Wu S; Chowdhury EA; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
[TBL] [Abstract][Full Text] [Related]
34. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Balthasar JP; Jusko WJ
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
[TBL] [Abstract][Full Text] [Related]
35. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs.
Davda JP; Jain M; Batra SK; Gwilt PR; Robinson DH
Int Immunopharmacol; 2008 Mar; 8(3):401-13. PubMed ID: 18279794
[TBL] [Abstract][Full Text] [Related]
36. Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties.
Hu S; Datta-Mannan A; D'Argenio DZ
MAbs; 2022; 14(1):2056944. PubMed ID: 35491902
[TBL] [Abstract][Full Text] [Related]
37. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.
Sharma A; Li M; Thavathiru E; Ibrahim M; Garcia-Contreras L; Benbrook DM; Woo S
AAPS J; 2020 Feb; 22(2):51. PubMed ID: 32086622
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic Characterization and Tissue Distribution of Fusion Protein Therapeutics by Orthogonal Bioanalytical Assays and Minimal PBPK Modeling.
Sugimoto H; Chen S; Qian MG
Molecules; 2020 Jan; 25(3):. PubMed ID: 31991858
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models.
Fronton L; Pilari S; Huisinga W
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):87-107. PubMed ID: 24493102
[TBL] [Abstract][Full Text] [Related]
40. Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.
Hudachek SF; Gustafson DL
J Pharmacokinet Pharmacodyn; 2013 Apr; 40(2):157-76. PubMed ID: 23315145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
